# Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.

> **NCT00370396** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1200 (actual)

## Conditions studied

- Infections, Streptococcal

## Interventions

- **BIOLOGICAL:** Synflorix
- **BIOLOGICAL:** Prevenar
- **BIOLOGICAL:** Infanrix hexa

## Key facts

- **NCT ID:** NCT00370396
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09-25
- **Primary completion:** 2007-06-04
- **Final completion:** 2007-11-06
- **Target enrollment:** 1200 (ACTUAL)
- **Last updated:** 2019-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00370396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00370396, "Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00370396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*